Drug Sponsors

Bayer to acquire Conceptus

Monday, April 29, 2013 10:50 AM

Bayer HealthCare has signed a merger agreement with Conceptus, a Mountain View, Calif.-based developer of the Essure procedure, a non-surgical permanent birth control method.

More... »

Eisai to establish new parenteral facility in China

Friday, April 26, 2013 12:28 PM

Eisai, a Japanese pharmaceutical company, has decided to establish a new parenteral facility on a lot retained by Eisai's Chinese subsidiary, Eisai China, at the Suzhou Industrial Park in Suzhou, China. 

More... »

OPKO Health to acquire Prolor Biotech

Wednesday, April 24, 2013 10:43 AM

OPKO Health, a multinational biopharmaceutical and diagnostics company, has signed a definitive merger agreement to acquire Prolor Biotech, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins, in an all-stock transaction. 

More... »

Auris Medical secures $50M Series C financing for inner ear

Wednesday, April 17, 2013 10:15 AM

Auris Medical, a Swiss biotechnology company focused on novel therapeutics for the treatment of inner ear disorders, has completed a $50 million Series C financing. Two leading venture capital firms, Sofinnova Ventures  of Menlo Park, Calif., and Sofinnova Partners of Paris, participated in the financing.

More... »

Merck opens new manufacturing facility in Hangzhou, China

Tuesday, April 16, 2013 02:05 PM

Global healthcare company Merck has opened its new pharmaceutical manufacturing facility in Hangzhou, China. The facility, located in the Hangzhou Economic and Technology Area (HEDA), will package Merck medicines for China and the Asia Pacific region and will become a critical part of Merck's global supply chain. 

More... »

Thermo Fisher Scientific to acquire Life Technologies

Tuesday, April 16, 2013 11:29 AM

Thermo Fisher Scientific, a healthcare equipment company, has signed a definitive agreement to acquire Life Technologies, a global biotechnology tools company, for $76.00 in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of net debt at close ($2.2 billion as of year end 2012).

More... »

Royalty Pharma makes firm offer to acquire Elan

Tuesday, April 16, 2013 09:41 AM

Echo Pharma Acquisition (Royalty Pharma) announced the terms of a firm, all cash offer for the entire issued and to be issued share capital of Elan. 

More... »

BMS to spend $250M to expand biologics facility, create 350 jobs

Friday, April 12, 2013 10:43 AM

Bristol-Myers Squibb (BMS) is planning a $250 million expansion of its large-scale biologics manufacturing facility in Devens, Mass. The expansion will introduce biologics development and clinical trial manufacturing capabilities to the site, while adding approximately 350 employees to the Devens workforce over time.

More... »

Cleave Biosciences raises $10M in Series A Financing extension

Wednesday, April 10, 2013 11:13 AM

Cleave Biosciences has raised $10 million in an extension of its Series A financing from new investor New Enterprise Associates (NEA), bringing its Series A total to $54 million. In conjunction with the financing, NEA partner Robert Garland, M.D., has joined Cleave's board of directors.

More... »

Unigene secures financing to extend operations, cuts 40% of staff

Tuesday, April 9, 2013 08:00 AM

Unigene Laboratories, a biopharmaceutical company focused on peptide-based therapeutics, has entered into a second amendment to a financing agreement with affiliates of Victory Park Capital Advisors (VPC), whereby VPC has agreed to purchase an additional $750,000 senior secured note, providing Unigene with additional working capital.

More... »